VSEE Reports Revenue Growth But Losses Deepen 144%

VSee Health (VSEE) reported its fiscal 2025 Q4 earnings on March 31, 2026. The company posted a 5.1% year-over-year revenue increase but saw its net loss widen significantly. While revenue growth was positive, the substantial increase in losses raised concerns among investors.

Revenue

VSee Health’s total revenue for 2025 Q4 climbed by 5.1% to $3.93 million, compared to $3.73 million in the same period of the prior year. This modest gain reflects ongoing efforts to expand its telehealth and SaaS offerings, though it remains below the broader growth seen in the company’s full-year 2025 10-K filing.

Earnings/Net Income

The company’s financial performance worsened in the bottom line. Per-share losses expanded to $0.24 in Q4 2025, from $0.20 in Q4 2024. Net loss surged to $-7.85 million in the latest quarter, a 144.7% increase from the $-3.21 million loss in the year-ago period. Despite a slight improvement in gross margin and a 40% year-over-year revenue jump in the full fiscal year, the Q4 results highlight ongoing operational challenges and cost pressures. The net loss per share and growing deficit signal that profitability remains elusive.

Price Action

VSee Health’s stock price reacted mixedly in the short term. The shares rose by 8.46% during the latest trading day, but this momentum reversed in the following days, with a 3.85% decline over the most recent full trading week. More significantly, the stock has dropped 32.25% month-to-date, reflecting broader market pessimism. The post-earnings performance underscores investor skepticism regarding the company’s ability to turn around its earnings trajectory and mitigate losses.

Post-Earnings Price Action Review

The strategy of buying VSee Health (VSEE) shares on the date of quarterly earnings releases and holding for 30 days showed poor performance over the past three years. The cumulative return was -39.8%, significantly underperforming the market. This indicates the strategy suffered from both timing and market sector risks, with the tech sector facing additional challenges that worsened performance.

CEO Commentary

The CEO of VSee Health highlighted that the company achieved a 5.1% revenue increase in Q4 2025, reflecting continued demand for its telehealth and SaaS platform. However, the CEO acknowledged the significant net loss of $7.85 million, attributing it to increased operational costs and investments in expanding ICU telemedicine and HHS contract work. The leadership expressed cautious optimism about the long-term potential of the business, emphasizing strategic initiatives such as enhancing platform capabilities and growing high-acuity telecritical care through the iDoc acquisition.

Guidance

Additional News

In late March 2026, VSee Health completed the acquisition of iDoc, a move that significantly contributed to its 40% year-over-year revenue growth for the full 2025 fiscal year. The integration of iDoc expanded VSee’s capabilities in telecritical care, positioning the company to better serve high-acuity healthcare settings. Additionally, the company announced an increase in staffing and equipment investments to scale ICU telemedicine operations. No executive changes or shareholder returns such as dividends or buybacks were disclosed within the three weeks following the March 31 earnings report.